ResMed (NYSE:RMD) (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.
ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders. The company also supplies ventilators and respiratory care solutions for use in both home and clinical settings. Complementing its hardware, ResMed offers cloud-based software platforms and patient engagement tools that enable remote monitoring, data analytics and care management for healthcare professionals and homecare providers.
ResMed serves a broad global market, including sleep clinics, hospitals, home healthcare providers and individual patients across North America, Europe, Asia-Pacific and other regions. The company emphasizes research and development, regulatory compliance and partnerships with healthcare stakeholders to expand access to diagnosis and long-term management of respiratory conditions.
ResMed is led by President and Chief Executive Officer Michael J. “Mick” Farrell and maintains a strategic focus on integrating digital health and connectivity with its device offerings to improve therapy adherence, enable remote care delivery and support value-based models for chronic respiratory disease management.
